U.S. markets closed
  • S&P Futures

    3,879.25
    +11.75 (+0.30%)
     
  • Dow Futures

    31,450.00
    +92.00 (+0.29%)
     
  • Nasdaq Futures

    13,112.50
    +57.25 (+0.44%)
     
  • Russell 2000 Futures

    2,245.80
    +16.70 (+0.75%)
     
  • Crude Oil

    59.97
    +0.22 (+0.37%)
     
  • Gold

    1,731.60
    -2.00 (-0.12%)
     
  • Silver

    26.78
    -0.09 (-0.35%)
     
  • EUR/USD

    1.2088
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.4150
    -0.0310 (-2.14%)
     
  • Vix

    24.10
    +0.75 (+3.21%)
     
  • GBP/USD

    1.3959
    +0.0003 (+0.02%)
     
  • USD/JPY

    106.8460
    +0.1360 (+0.13%)
     
  • BTC-USD

    48,696.54
    -677.27 (-1.37%)
     
  • CMC Crypto 200

    976.11
    -10.54 (-1.07%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,459.71
    +51.54 (+0.18%)
     

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2020 Financial Results on April 30, 2020

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2020 financial results on Thursday, April 30, 2020 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Thursday, April 30, 2020
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

REPLAY access

  • Telephone replay will be available beginning at approximately 4:30 p.m. PT on Thursday, April 30, 2020 through 5:00 p.m. PT on Sunday, May 3, 2020 by calling 888-203-1112 (domestic) or +1 719-457-0820 (international); conference ID 7835915

  • Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors section

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the company’s industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. In addition, investigational agent tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200413005032/en/

Contacts

Investors
Peggy Pinkston
(425) 527-4160
ppinkston@seagen.com

Media
Monique Greer
(425) 527-4641
mgreer@seagen.com